Cargando…
Brain proteomic changes by histone deacetylase inhibition after traumatic brain injury
BACKGROUND: Traumatic brain injury (TBI) is a leading cause of morbidity and mortality. There are currently no cytoprotective treatments for TBI. There is growing evidence that the histone deacetylase inhibitor valproic acid (VPA) may be beneficial in the treatment of TBI associated with hemorrhagic...
Autores principales: | Pumiglia, Luke, Williams, Aaron M, Kemp, Michael T, Wakam, Glenn K, Alam, Hasan B, Biesterveld, Ben E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993337/ https://www.ncbi.nlm.nih.gov/pubmed/33880414 http://dx.doi.org/10.1136/tsaco-2021-000682 |
Ejemplares similares
-
Validation of intraosseous delivery of valproic acid in a swine model of polytrauma
por: Biesterveld, Ben E, et al.
Publicado: (2021) -
Factors Associated with Increased Risk of Patient No-Show in Telehealth and Traditional Surgery Clinics
por: Kemp, Michael T., et al.
Publicado: (2020) -
Surgery Provider Perceptions on Telehealth Visits During the COVID-19 Pandemic: Room for Improvement
por: Kemp, Michael T., et al.
Publicado: (2021) -
Comparative analysis of isoform-specific and non-selective histone deacetylase inhibitors in attenuating the intestinal damage after hemorrhagic shock
por: Bhatti, Umar F, et al.
Publicado: (2019) -
Histone Deacetylase Inhibitors: A Novel Strategy for Neuroprotection and Cardioprotection Following Ischemia/Reperfusion Injury
por: Pickell, Zachary, et al.
Publicado: (2020)